The immune system in action

ImmunoScape enables the characterization of a patient’s immune profile at unprecedented resolution.  Our assays provide a view into the immune system in action, directly observing T cell phenotype & function with simultaneous tracking of TCR-antigen binding.

When combined with our deep analytics platform and in-house expertise, we enable the discovery of novel immune insights from millions of cells derived from blood or tissues of interest.

Immune Insights

Our technology and services empower researchers and drug developers to:

  • Discover novel vaccine, antibody, or cell therapy targets
  • Evaluate treatment outcomes through longitudinal studies
  • Design successful clinical trials through efficient patient enrollment
  • Uncover combinations of predictive biomarkers of disease or treatment efficacy
  • Demonstrate proof-of-mechanism in tissues of interest

 

The ImmunoScape Difference

 

Developed over the past decade, ImmunoScape’s unique capabilities combine reliable and sensitive rare event detection with single-cell resolution, our sophisticated high-dimensional reduction and proprietary algorithms, and the deep immunological expertise of our team to deliver new insight into what the immune system is actually doing, and how T cells change as they respond to specific antigens.

 

Reliable and sensitive detection of rare events

Reliable and sensitive detection is critical in rare event analysis. ImmunoScape uses proven tetramer technology as the foundation for single-cell, high-dimensional, rare-event detection.

In a 2009 Nature Methods paper, published by Newell et al., the simultaneous use of large numbers of different peptide-MHC Class I (pMHC-I) tetramers on cells using standard flow cytometry and reagents was demonstrated.

Due to the limitations of flow cytometry, including crosstalk between the limited repertoire of then available fluorophores, the tetramer multiplexing method was extended to a mass cytometry platform (CyTOF®) to enable broader and deeper profiling of antigen-specific T cells.

Using ten metal labels with combinatorial MHC-I tetramer staining in unique combinations of three metal labels per MHC multimer, 120 antigen specificities can be screened per sample, with a substantial number of labels, i.e. 30 or more, still available for parallel phenotyping and functional analysis of the T cells.

Tetramers enable analysis of the characteristics of the antigen-specific T cells ex vivo without perturbing the cells or changing their phenotypes. Cells are stained for a very short period of time at low temperature so they retain their phenotypes and can even be detected in a completely dysfunctional state.

ImmunoScape’s Core Technology

ImmunoScape’s unique capabilities can deliver key insights on antigen-specific T cells in studies of cancer such as immune checkpoint blockade, therapeutic and prophylactic vaccines, and T cell therapeutics, as well as in infectious and autoimmune diseases.

To home in on antigen-specific T cell responses, optimized tetramers for high avidity TCR-antigen staining plus combinatorial coding algorithms enable deep multiplexing. Profound insights are provided by tracking greater than 30 phenotypic markers as well as greater than 100 antigen specificities in a single sample.

 

ImmunoScape integrates leading technology platforms together with our deep immunological and bioinformatic expertise into an end-to-end solution.

ImmunoScape’s Bioinformatic tools, Cytographer® , can integrate and correlate deep immune profiling and antigen-specific mass cytometry data with single cell TCR repertoire analysis providing an unsurpassed deep characterization of a patient’s immune profile.

Top